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SUMMARY
Conflict procedures can be used to study the receptor mechanisms underlying the anxiolytic effects
of benzodiazepines and other GABAA receptor modulators. In the present study, we first determined
the efficacy and binding affinity of the benzodiazepine diazepam and recently synthesized
GABAA receptor modulators JY-XHe-053, XHe-II-053, HZ-166, SH-053-2'F-S-CH3 and
SH-053-2'F-R-CH3 at GABAA receptors containing α1, α2, α3 and α5 subunits. Results from these
studies suggest that each compound displayed lower efficacy at GABAA receptors containing α1
subunits and varying degrees of efficacy and affinity at GABAA receptors containing α2, α3 and
α5 subunits. Next, we assessed their anxiolytic effects using a rhesus monkey conflict procedure in
which behavior was maintained under a fixed-ratio schedule of food delivery in the absence (non-
suppressed responding) and presence (suppressed responding) of response-contingent electric shock.
Relatively non-selective compounds, such as diazepam and JY-XHe-053 produced characteristic
increases in rates of suppressed responding at low to intermediate doses and decreased the average
rates of non-suppressed responding at higher doses. XHe-II-053 and HZ-166 also produced increases
in suppressed responding at low to intermediate doses, but were ineffective at decreasing rates of
non-suppressed responding, consistent with their relatively low efficacy at GABAA receptors
containing α1 and α5 subunits. In contrast, SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 produced
only partial increases in suppressed responding and were ineffective on non-suppressed responding,
consistent with their profiles as partial agonists at GABAA receptors containing α2, α3 and α5
subunits. These behavioral effects suggest that the anxiolytic and rate-reducing effects of GABAA
receptor positive modulators are dependent on their relative efficacy and affinity at different
GABAA receptor subtypes.
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Benzodiazepine-type drugs act as positive allosteric modulators of γ-aminobutyric acid type
A (GABAA) receptors, and are highly efficacious agents for the treatment of anxiety-related
disorders. The therapeutic use of benzodiazepine-type drugs is constrained, however, by other
characteristic effects such as daytime drowsiness, impairment of motor coordination, memory
deficits, and reinforcing effects that may contribute to their abuse (Griffiths and Weerts,
1997; Nutt, 2005). Research during the past two decades has revealed the existence of multiple
subtypes of the GABAA receptor (e.g., Pritchett et al., 1989; Rudolph et al., 2001; Olsen and
Sieghart, 2008). Subsequent reports have postulated that the diverse behavioral effects of
benzodiazepine-type drugs may reflect actions at different subtypes of GABAA receptors
(Rudolph et al., 1999; McKernan et al., 2000; Löw et al., 2000; Rowlett et al., 2005). Therefore,
it may be possible to dissociate the clinically advantageous and unwanted side-effects of these
compounds.
GABAA receptors are pentameric proteins composed of several subunits that form a GABA-
gated chloride channel. The majority of GABAA receptors are composed of α, β , and γ subunits
and benzodiazepines bind predominantly to a site on the native GABAA receptor that is located
at the interface of the γ 2 subunit and one of the α1, α2, α3, or α5 subunits. Benzodiazepines
generally are inactive at corresponding α4- and α6-subunit containing receptors.
Approximately 90% of the GABAA receptors in the brain that possess a benzodiazepine
binding site contain α1, α2, and α3 subunits (McKernan and Whiting, 1996), and GABAA
receptors containing α1 subunits (α1GABAA receptors) have been implicated in the sedative
effects of benzodiazepines, whereas GABAA receptors containing α2 and α3 subunits
(α2GABAA and α3GABAA receptors) have been implicated in the anxiolytic effects of
benzodiazepines (McKernan et al., 2000; Löw et al., 2000; Rowlett et al., 2005; Dixon et al.,
2008). GABAA receptors containing α5 subunits (α5GABAA receptors), in contrast, are a
relatively minor population that may play a role in memory processes, but not anxiolysis or
motor effects (Collinson et al., 2002; Crestani et al., 2002; Atack et al., 2006, but see Savic et
al., 2008). Therefore, novel benzodiazepine-like drugs that have pharmacological selectivity
for α2GABAA and/or α3GABAA receptors and low receptor activity at α1GABAA and
α5GABAA receptors may be particularly useful as anxiolytics lacking sedative and amnestic
side effects.
The preclinical assessment of the anxiolytic effects of drugs can be accomplished objectively
and quantitatively with operant-based conflict procedures. In these procedures, positively
reinforced behavior is suppressed by response-contingent administration of a noxious stimulus
(e.g., mild electric shock; for review, see Millan 2003). Drugs with anxiolytic effects produce
characteristic increases in the rates of responding that are suppressed by response-contingent
delivery of shock (e.g., Geller and Seifter 1960; Cook and Davidson 1973; Kleven and Koek
1999; Rowlett et al., 2006), and a particular strength of conflict procedures is their predictive
validity with respect to therapeutic effects in humans. In this regard, strong positive correlations
between the potency of benzodiazepines to engender anti-conflict effects and to be clinically
effective in humans have been demonstrated in rats and pigeons (Cook and Davidson 1973;
Kleven and Koek 1999), and more recently in rhesus monkeys (Rowlett et al., 2006). A distinct
advantage in using rhesus monkeys in a conflict procedure arises from their close genetic
similarity to humans.
In the present study, we first assessed the efficacy and binding affinity of the conventional
benzodiazepine diazepam and the recently synthesized and structurally related positive
GABAA receptor modulators JY-XHe-053, XHe-II-053 and HZ-166. The efficacy and binding
affinity of the 4-methyl-JY-XHe-053 stereoisomers SH-053-2'F-S-CH3 and SH-053-2'F-R-
CH3 was also assessed. Each of the novel GABAA receptor modulators demonstrated
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lower efficacy at α1GABAA receptors relative to diazepam at the drug concentrations
that can be reached under our experimental conditions. Further, each compound
demonstrated varying degrees of either binding selectivity or relative efficacy for
α2GABAA, α3GABAA and α5GABAA receptor subtypes. The primary aim of the present
study was to help elucidate the role of these receptor subtypes in the anxiolytic effects of
benzodiazepines. Therefore, we used a rhesus monkey conflict procedure to assess the
anti-conflict and rate-reducing effects of these drugs. Based on studies suggesting that
benzodiazepine action at α1GABAA receptors contributes to their sedative effects, whereas
α2GABAA and α3GABAA receptors are important for benzodiazepine-induced anxiolysis, our
hypothesis was that the novel GABAA receptor modulators would have anti-conflict effects





acid ethyl ester), XHe-II-053 (8-ethynyl-6-phenyl-4H-2,5,10b-triaza-benzo[e]azulene-3-
carboxylic acid ethyl ester), HZ-166 (8-ethynyl-6-(2’-pyridine)-4H-2,5,10b-triaza-benzo[e]
azulene-3-carboxylic acid ethyl ester), SH-053-S-CH3-2’F (the S-enantiomer of 4-methyl-JY-
XHe-053; (S)-8-ethynyl-6-(2-fluoro-phenyl)-4-methyl-4H-2,5,10b-triaza-benzo[e]azulene-3-
carboxylic acid ethyl ester) and SH-053-R-CH3-2’F (the R-enantiomer of 4-methyl-JY-
XHe-053; (R)-8-ethynyl-6-(2-fluoro-phenyl)-4-methyl-4H-2,5,10b-triaza-benzo[e]
azulene-3-carboxylic acid ethyl ester) (Cook et al., 2009) were synthesized at the Department
of Chemistry and Biochemistry, University of Wisconsin-Milwaukee. JY-XHe-053, XHe-
II-053, HZ-166, SH-053-2'F-S-CH3 and SH-053-2'F-R-CH3 have a similar
pharmacokinetic profile and duration of action (Rivas et al., 2009; Cook et al., 2010).
Diazepam was purchased from Tocris-Cookson (Ellisville, MO, USA). All drugs were
dissolved in 20% ethanol, 60% propylene glycol, and 20% sterile water. If necessary, the pH
of a solution was adjusted to 7.0 with 1N HCl.
Competition Binding Assays
Competition binding assays were performed in a total volume of 0.5 mL at 4 ° C for 1 hour
using [3H]flunitrazepam as the radiolabelled ligand. A total of 6 μg of cloned human
GABAA receptor DNA containing desired α subtype along with β2 and γ2 subunits were used
for transfecting HEK 293T cell line using Fugene 6 (Roche Diagnostic) transfecting reagent.
Cells were harvested 48 hrs after transfection, washed with Tris-HCl buffer (pH 7.0) and Tris
Acetate buffer (pH 7.4) and resulting pellets were stored at −80 C until assayed. On the day of
the assay, pellets containing 20–50 μg of GABAA receptor protein were re-suspended in (50
mM Tris-acetate pH 7.4 at 4 degree) and incubated with the radiolabel as previously described
(Choudhary et al., 1992). Nonspecific binding was defined as radioactivity bound in the
presence of 100 μM diazepam and represented less than 20% of total binding. Membranes were
harvested with a Brandel cell harvester followed by three ice-cold washes onto
polyethyleneimine-pretreated (0.3%) Whatman GF/C filters. Filters were dried overnight and
then soaked in Ecoscint A liquid scintillation cocktail (National Diagnostics; Atlanta, GA).
Bound radioactivity was quantified by liquid scintillation counting. Membrane protein
concentrations were determined using an assay kit from Bio-Rad (Hercules, CA) with bovine
serum albumin as the standard.
Electrophysiological experiments
cDNAs of rat GABAA receptor subunits were used for generating the respective mRNA′s that
were then injected into Xenopus laevis oocytes (Nasco, WI) as described previously (Savic et
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al., 2008). For electrophysiological recordings, oocytes were placed on a nylon-grid in a bath
of Xenopus Ringer solution (XR, containing 90 mM NaCl, 5 mM HEPES-NaOH (pH 7.4), 1
mM MgCl2, 1 mM KCl and 1 mM CaCl2). The oocytes were constantly washed by a flow of
6 ml/min XR which could be switched to XR containing GABA and/or drugs. Drugs were
diluted into XR from DMSO-solutions resulting in a final concentration of 0.1 % DMSO
perfusing the oocytes. Drugs were pre-applied for 30 sec before the addition of GABA, which
was co-applied with the drugs until a peak response was observed. Between two applications,
oocytes were washed in XR for up to 15 min to ensure full recovery from desensitization. For
current measurements the oocytes were impaled with two microelectrodes (2–3 m?Ω) which
were filled with 2 mM KCl. All recordings were performed at room temperature at a holding
potential of −60 mV using a Warner OC-725C two-electrode voltage clamp (Warner
Instruments, Hamden, CT). Data were digitised, recorded and measured using a Digidata
1322A data acquisition system (Axon Instruments, Union City, CA).
Animals
Behavioral subjects were individually housed adult rhesus monkeys (Macaca mulatta)
maintained at 90–95% of their free-feeding weights. Aside from experimental procedures,
monkeys were maintained on a 12-hr lights-on/12-hr lights-off cycle (lights on at 7:00 AM)
and water was available continuously. All testing procedures were conducted prior to 12 noon.
Monkeys were prepared with chronic indwelling venous catheters according to the procedures
described by Platt et al. (2005). Throughout all testing the National Institutes of Health guide
for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) was
adhered to, and the experimental procedures were approved by the Harvard Medical School
Institutional Animal Care and Use Committee (Standing Committee on Animals). All efforts
were made to minimize animal suffering, to reduce the number of animals used, and to utilize
alternatives to in vivo techniques, if available.
Conflict Procedure
Four male and two female rhesus monkeys were trained on a multiple schedule of reinforcement
as described in detail by Rowlett et al. (2006). Monkeys had various durations of exposure
to this procedure, and these times ranged from 1–8 years. A daily session consisted of 4
cycles, each preceded by a 10 min time out period in which all lights in the chamber were off
and responding had no programmed consequences. Each cycle consisted of two components.
The first component was signaled by red stimulus lights and consisted of a fixed ratio 18 (FR18)
schedule of food pellet delivery (Bioserve, Frenchtown, NJ) followed by a 10 s time out. The
second component, signaled by green stimulus lights, consisted of the FR 18 schedule of food
delivery combined with a FR 20 schedule of foot shock delivery (1.5–3.0 mA, adjusted for
each monkey based on individual performance, 0.25 s duration). Delivery of a food pellet was
followed by a 10 s time out in which responding had no scheduled consequences. Both
components were 5 min in duration, or ended after the monkey obtained 5 food pellets or
received 3 foot shocks, whichever occurred first.
Test sessions were conducted once or twice per week when monkeys reached stable
performance, defined as the average rates of responding for component 1 and component 2 not
varying by ± 20% over five consecutive sessions, with no upward or downward trends. During
test sessions, i.v. injections of vehicle or drug were administered in the 5th minute of each time
out (i.e., 5 min prior to the beginning of each cycle). In successive cycles, increasing doses
of the test drug were administered using a cumulative dosing procedure. The dependent
measure was the average rates of responding (responses/s), calculated by dividing responses
by time during components 1 and 2, excluding responding during time outs or reinforcer
delivery.
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Effects of doses of compounds were evaluated by conducting a priori Bonferroni t-tests,
comparing individual doses to vehicle injection with an alpha level set at p ≤ 0.05. Potency
values (dose engendering 50% maximum effect, ED50) were calculated in individual monkeys
by log-linear regression when at least three data points were available on the linear portion of
the dose-effect curve or by interpolation when only two data points (one above and one below
50%) were available. Individual ED50 values were converted to their log values for calculation
of means and SEM and then converted back to linear values for presentation.
RESULTS
In Vitro Profiles
Table 1 shows the in vitro binding affinity of diazepam, JY-XHe-053, XHe-II-053 and HZ-166
and the 4-methyl-JY-XHe-053 stereoisomers SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 at
GABAA receptor subtypes. The six compounds produced a relatively broad range of affinities
across the receptor subtypes, with no compound demonstrating substantial selectivity for a
particular receptor subtype. JY-XHe-053 and SH-053-2’F-R-CH3 were the most selective
compounds across GABAA receptor subtypes, displaying 18- and 8- fold selectivity for
α5GABAA receptors, respectively.
Table 2 shows the in vitro efficacy data at presumed physiologically relevant concentrations
of 100 nM and 1μM for diazepam, JY-XHe-053, XHe-II-053, HZ-166, SH-053-2’F-S-CH3
and SH-053-2’F-R-CH3 as the percentage of control current. Relative to diazepam, the efficacy
values were reduced at α1GABAA across all five compounds, with JY-XHe-053 exerting the
greatest positive modulation and SH-053-2’F-R-CH3 exerting the least positive modulation.
The efficacy values for each compound were also reduced at α2GABAA and α3GABAA
receptors relative to diazepam, but were larger than their respective values at α1GABAA
receptors. JY-XHe-053 and SH-053-2’F-R-CH3 exerted the greatest and least positive
modulation at α2GABAA and α3GABAA receptors, respectively. Relative to diazepam, the
efficacy values for JY-XHe-053, XHe-II-053 and HZ-166 were reduced at α5GABAA
receptors, while the efficacy values for SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 were
either decreased or increased, depending on the concentration considered. HZ-166 exerted the
least positive modulation while SH-053-2'F-S-CH3 exerted the greatest positive modulation at
α5GABAA receptors.
Anti-Conflict Effects of 8-acetylene imidazobenzodiazepines
Figure 2 shows the effects of diazepam, JY-XHe-053, XHe-II-053, HZ-166 on the fixed-ratio
schedule of food pellet delivery (non-suppressed responding) and the concurrent schedule of
food delivery and electric shock presentation (suppressed responding). Following vehicle
administration, rates of responding during both components were similar to those observed
during training sessions (i.e. between 2.0–3.0 responses/s during the non-suppressed
component, and less that 0.1 responses/s during the suppressed component). Diazepam and
JY-XHe-053 increased the mean rates of suppressed responding and was significantly different
compared to vehicle at doses of 0.3- 1.0 mg/kg, resulting in mean ED50 values (±SEM) of 0.18
(0.14–0.24) and 0.15 (0.09–0.25) mg/kg for diazepam and JY-XHe-053, respectively. In
addition, both diazepam and JY-XHe-053 attenuated the rates of non-suppressed responding
at a dose of 3.0 mg/kg, resulting in ED50 values of 1.1 (0.88–1.3) and 2.2 (1.7–2.9) mg/kg for
diazepam and JY-XHe-053, respectively.
XHe-II-053 and HZ-166 produced similar increases in the rates of suppressed responding at
doses of 1.0–10.0 mg/kg, resulting in an ED50 value of 0.71 (0.56–0.90) mg/kg for XHe-II-053
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and an ED50 value of 0.80 (0.57–1.1) mg/kg for HZ-166. Across a 30-fold dose range, neither
XHe-II-053 nor HZ-166 affected response rates during the non-suppressed component.
Anti-conflict effects of 4-methyl-JY-XHe-053 stereoisomers
Figure 3 shows the anti-conflict effects of the 4-methyl-JY-XHe-053 stereoisomers
SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 on non-suppressed and suppressed responding.
Following vehicle administration, rates of responding during both components were similar to
those observed during training sessions (i.e. between 2.0–3.0 responses/s during the non-
suppressed component, and less that 0.1 responses/s during the suppressed component).
SH-053-2’F-S-CH3 produced significant increases in suppressed responding [F(5,23)=3.134,
p<0.05], resulting in an ED50 value of 0.82 (0.58–1.2) mg/kg, however Bonferroni tests
suggested that there was no significant differences between any dose of SH-053-2’F-S-CH3
and vehicle. SH-053-2’F-R-CH3 produced partial increases in the mean rates of suppressed
responding, resulting in an ED50 value of 3.4 (2.3–5.2) mg/kg, however this effect did not reach
statistical significance [F(3,15)=2.750, not significant (n.s.)]. Across the dose range tested,
neither SH-053-2’F-S-CH3 nor SH-053-2’F-R-CH3 affected response rates during the non-
suppressed component across the dose range tested.
As evident from the results of the statistical analyses described above, the findings with
SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 were associated with a relatively high degree of
variance. To assess the source of variability more closely, we analyzed suppressed responding
across individual monkeys (Figure 3). SH-053-2’F-S-CH3 produced increases in suppressed
responding that reached or exceeded non-suppressed control levels in three of the monkeys
tested, and produced partial (~50%) increases in suppressed responding in the fourth monkey.
SH-053-2’F-R-CH3 produced increases in suppressed responding up to levels of non-
suppressed responding in two monkeys tested, and either a partial increase or no effect in the
other two monkeys.
DISCUSSION
The purpose of the present study was to characterize the potential anxiolytic-like effects of five
novel 8-acetylene imidazobenzodiazepines: JY-XHe-053, XHe-II-053, HZ-166, SH-053-2’F-
S-CH3 and SH-053-2’F-R-CH3. Each of the compounds demonstrated a reduced positive
modulation at α1GABAA receptors relative to the prototypical benzodiazepine diazepam
at the drug concentrations that can be reached under our experimental conditions.
Potentiation of GABA at α2GABAA and α3GABAA receptors was also lower relative to
diazepam; however the efficacy value at these receptor subtypes was greater than the
α1GABAA efficacy value across each of the compounds. Additionally, each compound
produced varying degrees of potentiation at α5GABAA receptors, with SH-053-2’F-S-CH3
and SH-053-2’F-R-CH3, the active isomers of 4-methyl-JY-XHe-053, exceeding those
produced by diazepam.
Behavioral procedures that assess the effects of drugs on experimentally-induced conflict are
used often to assess the potential anxiolytic effects of these drugs in humans (Geller and Seifter,
1962; Spealman, 1979; Kleven and Koek, 1999; Rowlett et al., 2006). The anti-conflict effects
of a series of conventional benzodiazepines with nonselective efficacy across α1GABAA,
α2GABAA, α3GABAA, and α5GABAA receptors subtypes has been described (Rowlett et al.,
2006). In the present study, diazepam produced behavioral effects that were consistent with
those of previously reported findings: it engendered a robust anti-conflict effect at low to
intermediate doses that was both graded and dose-dependent. Further, this effect occurred at
doses similar to those that would be predicted based on relative potencies for benzodiazepines
that are effective in the clinic (Rowlett et al., 2006). Together, these observations provide
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further support for the use of the rhesus monkey conflict procedure in predicting the anxiolytic
effects of drugs in humans.
The main finding from these experiments is that, similar to diazepam, the novel compounds
JY-XHe-053, XHe-II-053 and HZ-166 produced increases in positively reinforced behavior
that was suppressed by response-contingent electric shock. In contrast, SH-053-2’F-S-CH3
and SH-053-2’F-R-CH3 produced increases in suppressed responding in some monkeys and
not others, with the average data for SH-053-2’F-R-CH3 not reaching statistical significance.
Among the novel compounds studied, only JY-XHe-053 produced diazepam-like reductions
in rates of non-suppressed responding. These findings suggest that the anxiolytic and rate-
reducing effects of benzodiazepines and other GABAA receptor positive modulators are
dependent on their relative efficacy and affinity at GABAA receptor subtypes.
Previous studies from our laboratory also have used the rhesus monkey conflict procedure to
assess the anxiolytic effects of other GABAA receptor positive modulators with either selective
affinity or selective efficacy for GABAA receptor subtypes (Licata et al., 2005; Rowlett et al.,
2005; Rowlett et al., 2006). Results from these studies provide evidence for a differential role
of GABAA receptors in the anxiolytic effects of benzodiazepines. As an example, L-838,417,
a drug with functional selectivity and partial agonist activity at α2GABAA, α3GABAA, and
α5GABAA receptors, produced an anti-conflict effect similar to conventional non-selective
benzodiazepines (Rowlett et al, 2005). A similar result was observed when SL651498, a drug
with high intrinsic efficacy at α2GABAA and α3GABAA receptors, was assessed in the
conflict procedure (Licata et al., 2005). Together with data suggesting that drugs selective for
α1GABAA receptors (e.g. zolpidem, zaleplon) are only marginally effective in this procedure
(Rowlett et al., 2005; Rowlett et al., 2006), these experiments have supported a key role for
α2GABAA and α3GABAA receptors, but not α1GABAA receptors, in benzodiazepine-induced
anxiolysis. Subsequent studies with TPA023 (a drug with partial agonist properties at
α2GABAA and α3GABAA receptors) in other rodent and primate models of anxiety have
supported this hypothesis (Atack et al., 2006).
In the present study, the in vitro electrophysiology experiments suggest that XHe-II-053 and
HZ-166 have high intrinsic efficacy at α2GABAA and α3GABAA receptor subtypes relative
to their efficacy at α1GABAA and α5GABAA receptor subtypes. When XHe-II-053 and
HZ-166 were assessed in the conflict procedure, each produced an anti-conflict effect that was
quantitatively similar to diazepam. Together, these data provide further evidence that
compounds with selective efficacy at α2GABAA and α3GABAA receptors can produce
anxiolytic effects in primates. Over the dose range tested, XHe-II-053 and HZ-166 produced
an anti-conflict effect without producing diazepam-like alterations in non-suppressed
responding. The lack of response rate-suppressing effects of HZ-166 and XHe-II-053 is similar
to our previous results with L-838,417 and SL651498 (Rowlett et al., 2005; Licata et al.,
2005), and it is noteworthy that each compound (XHe-II-053, HZ-166, L-838,417 and
SL651498) has reduced efficacy at α1GABAA receptors relative to diazepam. These findings
support the idea that the α1GABAA receptor subtype may be involved in the response rate-
reducing effects of benzodiazepines at doses greater than those that produce anxiolysis.
Similar to the pharmacological profile of XHe-II-053 and HZ-166, the electrophysiological
experiments suggest that JY-XHe-053 has preferential activity at α2GABAA and α3GABAA
receptor subtypes. In agreement with the hypothesis that α2GABAA and/or α3GABAA
receptors mediate the anxiolytic effects of benzodiazepines, JY-XHe-053 also produced a
robust anti-conflict effect. Unlike XHe-II-053 and HZ-166 however, JY-XHe-053 also
produced significant reductions in response rates at the highest dose tested. This finding was
unexpected, considering the relatively low intrinsic efficacy of JY-XHe-053 at α1GABAA
receptors. However, it is interesting to note that, relative to XHe-II-053 and HZ-166, JY-
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XHe-053 has both greater efficacy at and greater affinity for α1GABAA receptors. These
observations support the hypothesis that α2GABAA and α3GABAA receptors mediate the
anxiolytic effects of benzodiazepines, and also raise the possibility that the subtle differences
at α1GABAA receptors between JY-XHe-053 and the other compounds may be sufficient for
rate-reducing effects.
In contrast to the diazepam-like anti-conflict and rate-reducing effects observed with JY-
XHe-053, the two isomers of 4-methyl-JY-XHe-053, SH-053-2’F-S-CH3 and SH-053-2’F-R-
CH3 produced relatively weak increases in suppressed responding and failed to produce
significant decreases in non-suppressed responding. The reasons for these differences are
unclear. Based on the in vitro data, the primary differences between the two isomers and the
parent compound were that (1) the affinities of the isomers were reduced considerably relative
to JY-XHe-053, (2) the efficacies of the isomers at the α5GABAA receptor were increased
relative to that of the parent compound and (3) the efficacy of SH-053-2’F-R-CH3 at
α2GABAA and α3GABAA receptors at the achievable drug concentrations was markedly
less than that of the parent compound. The relatively low potencies of the isomers may
have necessitated very high levels of compound for consistent effects, raising the
possibility that high enough concentrations were not sufficient in brain to for consistent
effects to occur. Additionally, it is interesting to note that among the compounds tested, both
SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 have substantial efficacy and high affinity for
α5GABAA receptors. In fact, in contrast to the other compounds and receptor subtypes,
SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 both exceed diazepam in efficacy at this subtype
when assessed at the physiologically relevant concentration of 1 μM. Therefore, the unexpected
finding that SH-053-2’F-R-CH3 lacked significant anti-conflict effects may result from its
pharmacological action at α5GABAA receptors coupled with its low efficacy at α2GABAA
and α3GABAA receptors. Further, the statistically significant but weak anti-conflict effects of
SH-053-2’F-S-CH3 may also be a consequence of its unique pharmacological profile at
α2GABAA, α3GABAA, and α5GABAA receptors. Support for these hypotheses comes from
a recent report implicating α5GABAA receptors in benzodiazepine-induced psychomotor
effects (Savic et al., 2008), which the authors suggest may serve to mask anxiolysis as measured
in preclinical procedures.
The experiments described here provide further evidence that the anti-conflict effects of
benzodiazepines in non-human primates are likely mediated by different GABAA receptors
that contain distinct α subunits. Additionally, the results from this study suggest that it is
possible to separate anxiolytic-like effects from effects indicative of a general disruption of
behavior. Our findings provide further evidence that novel benzodiazepine-like drugs that have
pharmacological selectivity for α2GABAA and/or α3GABAA receptors and low receptor
activity at α1GABAA and α5GABAA receptors may be particularly useful as non-sedating
anxiolytics. Also, the results from our studies suggest that subtle differences in α1GABAA
receptor activation may be sufficient for the rate-reducing effects of benzodiazepine-like drugs.
Finally, our findings raise the possibility that exceptional activity at α5GABAA receptors may
blunt the anxiolytic-like effects of benzodiazepines, regardless of their pharmacology at other
receptor subtypes. Together, these observations should provide an important framework for
studying the role of different GABAA receptor subtypes in the behavioral effects of
benzodiazepine-type drugs, which in turn should help guide both the current clinical use of
benzodiazepines as well as the development of improved therapeutic agents for treating anxiety
disorders.
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Chemical structures of diazepam, JY-XHe-053, XHe-II-053, HZ-166, SH-053-2’F-S-CH3 and
SH-053-2’F-R-CH3.
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Anti-conflict effects of diazepam, JY-XHe-053, XHe-II-053 and HZ-166 in rhesus monkeys
trained under a multiple schedule of food presentation (non-suppressed responding) and food
+ shock presentation (suppressed responding). Abscissae, cumulative intravenous dose of drug
in mg/kg. Ordinates, response rate as responses per second. Each data point represents the mean
(± S.E.M.) from four monkeys. Points above “V” represent data after vehicle administration.
Asterisks represent significant differences relative to vehicle for suppressed responding and
daggers represent significant differences relative to vehicle for non-suppressed responding
(Bonferroni t-tests, p<0.05).
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Anti-conflict effects of SH-053-2’F-S-CH3 and SH-053-2’F-R-CH3 in rhesus monkeys trained
under a multiple schedule of food presentation (non-suppressed responding) and food + shock
presentation (suppressed responding). Abscissae, cumulative intravenous dose of drug in mg/
kg. Ordinates, response rate as responses per second. Top panels, each data point represents
the mean (± S.E.M.) from four monkeys. Points above “V” represent data after vehicle
administration. Bottom panels, data points represent the rate of suppressed responding in
individual monkeys. Dashed lines represent rates of non-suppressed responding after vehicle
administration.
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Table 2
Efficacy at αxβ 3γ 2 GABAA receptor subtypes as % of control current at 100 nM and 1 μM concentrations. Data
are presented as 100 nM/1 μM.
Compound α1 α2 α3 α5
Diazepam 239/314 426/536 437/752 274/342
JY-XHe-053 169/248 307/410 365/596 220/246
XHe-II-053 130/194 209/329 265/513 150/186
HZ-166 113/167 165/313 149/346 130/174
SH-053-2'F-S-CH3 116/164 170/348 138/301 218/389
SH-053-2'F-R-CH3 111/154 124/185 125/220 183/387
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